Cliff Dominy

Imagine a cancer therapy that literally poked holes in cancer cells, destroying them. Imagine that this therapy was approved by the federal Food and Drug Administration and was available to patients and their oncologists, and that it could cure your cancer. We imagine you would expect patients to clamor for this treatment, but this is where the imagination falls short, because this therapy exists and is approved, but it is not widely used. This treatment is chimeric antigen receptor T-cell therapy.

Predatory journals are stealing the identities of reputable scientists in false authorship scams to improve their credibility with prospective clients. Recent high-profile cases have caused reputational harm to authors and editors and have exposed weaknesses in our trust-based academic system. Prepublication screening of academic manuscripts, along with the reform of academic incentives, will probably be central components of an effective response.

Key Takeaways CRISPR-on-a-chip platforms combine nanoscale engineering with microfluidic chemistry to develop portable, high-sensitivity diagnostic assays. Different assays, including fluorescent reporting systems and graphene-based sensors, have distinct but potentially complementary strengths. When it comes to clinical diagnostic devices, three variables must be carefully considered—speed, cost, and sensitivity. The catch: you can only pick two [].